Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 1999, p. 2663-2670, Vol. 43, No. 11
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Accumulation of 3-Ketosteroids Induced by
Itraconazole in Azole-Resistant Clinical Candida
albicans Isolates
Patrick
Marichal,1,2,*
Jos
Gorrens,1
Leen
Laurijssens,1
Karen
Vermuyten,1
Carl
Van
Hove,3
Ludo
Le
Jeune,4
Peter
Verhasselt,5
Dominique
Sanglard,6
Marcel
Borgers,2
Frans C. S.
Ramaekers,2
Frank
Odds,1,
and
Hugo
Vanden Bossche1
Anti-Infectives Research
Departments,1 Immunology
Department,3 Analytical
Department,4 and Biotechnology
Department,5 Janssen Research Foundation,
Beerse, Belgium; Institut de Microbiologie, Centre
Hospitalier Universitaire Vaudois, Lausanne,
Switzerland6; and Department of
Molecular Cell Biology & Genetics, University Maastricht,
Maastricht, The Netherlands2
Received 20 May 1999/Returned for modification 11 August
1999/Accepted 1 September 1999
 |
ABSTRACT |
The effects of itraconazole on ergosterol biosynthesis were
investigated in a series of 16 matched clinical Candida
albicans isolates which had been previously analyzed for
mechanisms of resistance to azoles (D. Sanglard, K. Kuchler, F. Ischer,
J. L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents
Chemother., 39:2378-2386, 1995). Under control conditions, all
isolates contained ergosterol as the predominant sterol, except two
strains (C48 and C56). In isolates C48 and C56, both less susceptible
to azoles than their parent, C43, substantial concentrations (20 to
30%) of 14
-methyl-ergosta-8,24(28)-diene-3
,6
-diol (3,6-diol)
were found. Itraconazole treatment of C43 resulted in a dose-dependent inhibition of ergosterol biosynthesis (50% inhibitory concentration, 2 nM) and accumulation of 3,6-diol (up to 60% of the total sterols) together with eburicol, lanosterol, obtusifoliol,
14
-methyl-ergosta-5,7,22,24(28)-tetraene-3
ol, and
14
-methyl-fecosterol. In strains C48 and C56, no further increase of
3,6-diol was observed after exposure to itraconazole. Ergosterol
synthesis was less sensitive to itraconazole inhibition, as was
expected for these azole-resistant isolates which overexpress ATP-binding cassette transporter genes CDR1 and
CDR2. In addition to 3,6-diol, substantial amounts of
obtusifolione were found after exposure to itraconazole. This toxic
3-ketosteroid was demonstrated previously to accumulate after
itraconazole treatment in Cryptococcus neoformans and
Histoplasma capsulatum but has not been reported in
Candida isolates. Accumulation of obtusifolione correlated with nearly complete growth inhibition in these azole-resistant strains
compared to that found in the susceptible parent strain, although the
onset of growth inhibition only occurred at higher concentrations of
itraconazole. ERG25 and ERG26 are the only
genes assigned to the 4-demethylation process, of which the
3-ketoreductase is part. To verify whether mutations in these
ERG25 genes contributed to obtusifolione accumulation,
their nucleotide sequences were determined in all three related
isolates. No mutations in ERG25 alleles of isolates C48 and
C56 were found, suggesting that this gene is not involved in
obtusifolione accumulation. The molecular basis for the accumulation of
this sterol in these two strains remains to be established.
 |
INTRODUCTION |
The incidence of fungal infections
has increased during the last decade. Only a few classes of antifungal
compounds are available to treat these infections. One important class
consists of inhibitors of ergosterol biosynthesis. These include the
allylamines, inhibitors of squalene epoxidase; the morpholines, which
inhibit both the
14-reductase and the
8,7-isomerase; and the imidazoles and triazoles
(azoles), which interfere with the cytochrome P-450s catalyzing the
lanosterol 14
-demethylase and sterol
22-desaturation.
In patients with impaired immune responses, e.g., AIDS patients,
neutropenic patients, and patients receiving bone marrow or organ
transplants, a higher incidence of nonresponse to treatment is found
(40). Treatment failures may result from host-related
factors, abnormal drug pharmacokinetics, or resistance of the infecting
fungus to the agent used. Over the last 5 years, many studies have been
published to elucidate the underlying causes of clinical resistance to
azoles. These studies have been extensively reviewed (2-4, 6, 9,
11, 13, 15, 21, 25, 26, 38-40, 44). Several mechanisms have been
identified that contribute to fungal resistance to azoles. Probably the
most common mechanism is to effect a diminution of the active-compound
concentration at the target site. In the majority of cases studied
recently, this was the result of overexpression of efflux pumps
(8, 20, 27), but in earlier studies, permeability changes in
the plasma membrane were also found (12). Two types of
efflux transporters have been reported. The ATP-binding cassette type
(ABC transporters, e.g., CDR1 and CDR2) can
export a wide variety of azoles and unrelated chemicals, including
antifungal sterol synthesis inhibitors such as amorolfine and
terbinafine, which do not inhibit the action of cytochrome P-450s
(18, 28, 29). This group of proteins uses the energy freed
by the hydrolysis of ATP to effect the efflux of compounds out of the
cell. The so-called major facilitators (e.g., CaMDR1,
previously described as Benr) identified so far
in fungi have a much narrower substrate spectrum, so that only
hydrophilic azole compounds such as fluconazole are exported whereas
lipophilic azoles such as itraconazole are not affected
(27). The energy for this second class of pump is provided by the proton gradient across the membrane.
A second general type of azole resistance mechanism involves changes at
the level of the antifungal target. The primary target for azole
antifungals is the cytochrome P-450-catalyzed 14
-demethylation of
ergosterol precursors, encoded by ERG11 (also called
ERG16 or CYP51). Overexpression of this enzyme,
induced either by enhanced transcription or by gene or chromosomal
amplification, results in decreased susceptibility to azole antifungals
(5, 22). Point mutations in ERG11, such as Y132H
(tyrosine 132 is replaced with histidine), T315A (threonine 315 is
replaced with alanine), or R476K (arginine 476 is replaced with
lysine), have been shown to decrease the affinity of the target for
azoles (19, 30, 43). Numerous publications have listed other
ERG11 mutations but unfortunately do not include data on the
effect of the mutation on azole sensitivity.
The third way in which fungi achieve effective resistance to azoles is
to circumvent or compensate for the toxic consequences of the
azole-induced depletion of ergosterol and concomitant accumulation of
14-methylated precursors. For example, it was shown in
Saccharomyces cerevisiae that a strain deficient in Erg11p
activity only survived in the presence of a defect in
5,6-desaturase, encoded by the ERG3 gene
(16). ERG3-deficient strains of Candida
albicans were found to be azole resistant (17). It was
hypothesized that resistance to fluconazole was due to the combination
of the presence of substantial quantities of 14
-methyl-fecosterol and the absence of 14
-methyl-ergosta-8,24(28)-diene-3
,6
-diol (3,6-diol).
Despite the numerous recent molecular genetic studies on azole
resistance, little attention has been paid to the details of inhibition
of the ergosterol biosynthetic pathway in clinical azole-resistant
C. albicans strains. In this study, we have
investigated the effects of itraconazole on ergosterol
biosynthesis in a series of matched clinical isolates that were
biochemically characterized previously in the pivotal study of Sanglard
et al. (27).
 |
MATERIALS AND METHODS |
Strains.
The C. albicans strains used in this
study originated at the Institute of Microbiology (Centre Hospitalier
Universitaire Vaudois, Lausanne, Switzerland) and were isolated from
AIDS patients with oropharyngeal Candida infections.
Identification of the yeast isolates and their clonal relatedness were
described by Sanglard et al. (27). Yeasts were maintained as
glycerol stocks at
80°C. The inocula for each individual experiment
were prepared from these glycerol stocks to minimize the possible
influences of genotypic or phenotypic instability. Table
1 summarizes the biochemical characterization of the isolates.
MIC determination.
To verify that the strains showed azole
susceptibility phenotypes similar to the original published
characteristics, MICs were determined spectrophotometrically by a broth
microdilution method (24) based on the National Committee
for Clinical Laboratory Standards (NCCLS) M27A protocol
(23). The MIC was the lowest concentration that inhibited
growth by more than 50%; this endpoint showed the best reproducibility
and correlation with results from the NCCLS broth macrodilution method.
Quality control yeasts Candida krusei ATCC 6258 and
Candida parapsilosis ATCC 22019 were tested in parallel, and
for these organisms the MICs of the antifungals tested were in the
correct ranges (23).
Sterol synthesis experiments.
To study sterol synthesis in
C. albicans, yeasts were grown in 100 ml of CYG medium
(casein hydrolysate [Merck, Darmstadt, Germany], yeast extract
[Difco, Detroit, Mich.], and glucose, each at a concentration of
5 g liter
1) in 500-ml Erlenmeyer flasks in a
reciprocating shaker set at 100 strokes/min at 37°C as described
before (33). Radiolabeled [2-14C]acetate (5 µCi; specific activity, 58 µCi mmol
1) was added
immediately prior to inoculation. Itraconazole was dissolved in
dimethyl sulfoxide (DMSO) (10 mM stock solution; 7.05 mg
ml
1), further diluted in 100% DMSO, and added to the
incubation mixtures at a final solvent concentration of 0.1%. In
control experiments, a similar amount of DMSO was added. After 24 h of growth, cells were collected by centrifugation at 1,500 × g and the cell pellet was washed with saline (0.15 M NaCl) and
homogenized with acid-washed glass beads (diameter, 0.40 to 0.45 mm) in
a 20-ml scintillation vial in a Retsch laboratory mixer mill 2000 set
at maximum speed for 5 min. The homogenate was quantitatively separated
from the glass beads by sequential washing. The homogenates were
supplemented with 1 volume of 15% KOH dissolved in 90% ethanol and
saponified at 84°C. Nonsaponifiable lipids were extracted with 1 volume of n-heptane. The heptane extracts were scanned
spectrophotometrically from 200 to 330 nm to quantify sterols with a
5,7-conjugated double-bond system. At a wavelength of
281 nm,
5,7-desaturated sterols could be specifically
detected and quantified by using an
281 of 11,200. The
linearity of this method was checked against a standard curve obtained
with authentic ergosterol. Heptane extracts were then dried with a
stream of N2 and sterols were separated by both thin-layer
chromatography and high-performance liquid chromatography analysis as
described previously (36). Sterol fractions were identified
by reference to authentic standards and by gas chromatography-mass
spectrometry. To quantify the effect of itraconazole on growth under
these conditions, cell concentrations were determined with a Coulter
counter as described earlier (34). Cell clustering and size
were examined with a Becton Dickinson FACScalibur flow cytometer and by
phase-contrast microscopy.
PCR amplification and sequence analysis of C. albicans
ERG25 and ERG3 genes.
To amplify the
ERG25 gene encoding at least part of the 4-demethylase, we
used primers adjacent to the open reading frame using the sequence
deposited by Johnson et al. (GenBank accession no. AF051914). All
subsequent numbering is according to this sequence. Vector NTi was used
to detect optimal primer pairs to amplify the entire open reading
frame. As a sense primer, 5'ATTGTTATATTTCAACATATACATATTCC3' was used (nucleotides 7 to 35 of AF051914), whereas the antisense primer was 5'AAACATTGAGAAGTTGTACACATATACT3' (nucleotides
1065 to 1038 of AF051914). Heat-activatable AmpliTaq Gold
(Perkin-Elmer, Foster City, Calif.; 0.5 U) was used with 2.5 mM
MgCl2. DNA from C. albicans strains was prepared
by the Qiagen DNA extraction method according to the procedures of the
manufacturer with Zymolyase (60 U; 5,000 U g
1;
Arthrobacter lutens; Seikagaku Kogyo, Tokyo, Japan) used as the cell wall-degrading enzyme. The PCR parameters were 10 min at
94°C to activate the polymerase and then 30 cycles of 1 min of
annealing at 48°C, 2 min of elongation at 72°C, and 1 min of denaturation at 92°C. After the reaction, the 1,059-bp PCR product was cleaned up with a Qiagen PCR cleanup kit and a sample was separated
on a 1% agarose gel with Boehringer molecular weight standard VI. The
1,059-bp amplification products from the different isolates were
sequenced on both strands by using the following PCR primers and
internal primers every 300 bp (name, sequence, nucleotide position, and
direction): Ca ERG25-01, TTCCATCCATTATGTC, 458, sense; Ca
ERG25-02, CCGATTGTTTGGTGTC, 716, sense; Ca ERG25-03, GTTACCAGTGATAAGAC, 745, antisense; Ca ERG25-04,
CATGGTAAACATCTACC, 318, antisense; and Ca ERG25-05,
GTCTTCCATTAGTAATG, 103, sense. Primers were designed by
visual inspection of the sequence for stretches of 16 to 18 nucleotides
of normal composition (40 to 60% GC, no palindromes, no homopolymeric
stretches). Primers were ordered from Eurogentec (Seraing, Belgium) and
synthesized by the
-cyanoethylphosphoramidite method. Sequencing
reactions were performed with the ABI Prism BigDye Terminator Cycle
Sequencing Ready Reaction Kit used according to the instructions of the
manufacturer (Perkin-Elmer), except that half of the volume of
terminator mix was replaced with HalfTerm (GenPak Ltd., Brighton,
United Kingdom). Sequencing reactions were run on an Applied Biosystems
377 XL DNA sequencer (Perkin-Elmer). Sequences were assembled from the individual runs into single contig sequences with the aid of the Sequencher software (Gene Codes Corporation, Ann Arbor, Mich.). Ambiguity positions were scored by setting the threshold as low as 30%
(i.e., secondary peaks at 30% of the primary peak result in an
ambiguity call) and by inspecting all of the ambiguity calls on all
available readings. To amplify the ERG3 gene from the three related strains, similar techniques were used. Numbering of nucleotides is according to the sequence deposited by Miyazaki et al. (GenBank accession no. AF069752). As a sense primer,
5'ACAGTTTVVVATTTTCCTTCCAA3' was used (nucleotides 208 to 230 of AF069752), whereas the antisense primer was
5'CATCTTTGTTTTGGACCATTGACTAGAGCTCHHH3' (SacI restriction site plus nucleotides 1578 to 1554 of AF069752). PCR was
performed as described above. The 1,380-bp amplification products were
sequenced on both strands using the following PCR primers and internal
primers every 300 bp (name, sequence, nucleotide position, and
direction): Ca ERG3-01, CCCAGCTACTGATTTC, 683, sense; Ca
ERG3-02; TGAAATCAGTAGCTGG, 699, antisense; Ca ERG3-03,
TTACACTGGCCATCTG, 1071, sense; and Ca ERG3-04,
GCATGAGAAGCAAATGG, 1150, antisense.
 |
RESULTS |
MIC determination.
In previous papers, Sanglard et al.
described different resistance mechanisms in series of sequential
isogenic C. albicans isolates from five AIDS patients with
oropharyngeal candidiasis (27, 29, 31). The results from
these studies are summarized in Table 1. To verify that no changes in
susceptibility were induced during shipment or with the initial
subcultivation to prepare the glycerol stock, MICs of fluconazole,
ketoconazole, and itraconazole for all 16 isolates were redetermined.
In addition, the amphotericin B sensitivity was also measured. The
results obtained are summarized in Table
2. Taking the well-documented variation
of azole susceptibility testing into account (23, 41), an
excellent correlation between the two determinations with a correlation
coefficient of 0.87 was found, indicating that the sensitivities of the
strains were not significantly altered. Only minor differences in
amphotericin B sensitivity were found among the 16 isolates,
demonstrating that they were not cross-resistant to this polyene
antifungal.
Sterol synthesis experiments.
In a pilot study, the sterol
compositions of all 16 isolates grown under control conditions were
analyzed. The results are presented in Table
3. Under control conditions, most
isolates, except C48, C56, and to a lesser extent C26, contained
ergosterol as the only predominant sterol. In isolates C48 and C56,
both related to C43, substantial accumulation of 3,6-diol at a level as
high as 20 to 30% of the total sterols was found. In the related azole-sensitive isolate C43, this sterol comprised only 2.5% of the
sterols isolated. This 14-methylated dihydroxysterol is normally found
only after treatment with an azole as described initially by Ebert et
al. in Ustilago maydis treated with etaconazole
(7) and by Vanden Bossche et al. in C. albicans
(34). The three isolates from patient V were selected for
further sterol analysis, and the impact of itraconazole treatment on
these isolates was investigated. In Table
4, the growth yields and the effects of itraconazole on the cell counts and ergosterol contents of the three
isolates are summarized. The inhibition profiles for both of the
parameters measured are shown in Fig. 1.
Under control conditions, C43 reached a higher yield of cells as
measured by Coulter counter. At stationary phase, C43 samples (100-ml
culture) contained (201 ± 24) × 108 cells
compared to (127 ± 10) × 108 cells for C48 and
(111 ± 6) × 108 cells for C56. The Wilcoxon
rank-sum statistical analysis suggests that isolates C48 and C56
behaved significantly differently from isolate C43. It could be argued
that this decrease in yield was the result of a more pronounced
clustering because the Coulter counter does not discriminate between
single cells and multicellular clusters. To eliminate this possibility,
we checked the size distribution of the cultures with flow cytometry
and looked at the morphology in a microscope. In Fig.
2, the forward-scatter histograms are shown for all three isolates grown for 24 h in CYG medium. Under control conditions, both isolates C48 and C56 contained more single cells than did the C43 strain, represented on the graph by the S
region. The positions of the multicellular particle region (M) were
similar for all three isolates, indicating similar degrees of
clustering. This was confirmed by the microscopical examination. The
contents of
5,7diene-containing sterols (under control
conditions, ergosterol for all three strains) extracted from the
cultures were found to be similar in all three isolates (Table 4). This
implies a higher cellular ergosterol content in C48 (82 fg · cell
1) and C56 (83 fg · cell
1) than
in C43 (53 fg · cell
1). This latter value matches
that published by Hitchcock et al. (12). These authors found
total lipid and total sterol contents of 670 and 52 fg · cell
1, respectively, in C. albicans isolate A.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of itraconazole on C. albicans C43
( ), C48 ( ), and C56 ( ) after 24 h in shaken culture in
CYG medium. (a) Growth measured by Coulter counter. (b) Ergosterol
content measured by determining the A281 of a
heptane extract obtained from C43 ( ), C48 ( ), and C56 ( ). The
results shown are averages of at least three independent experiments.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Histograms of the forward scatter of cultures of
C. albicans C43 (a and b), C48 (c and d), and C56 (e and f)
grown for 24 h in CYG medium under control conditions (a, c, and
e) or after exposure to 3 µM itraconazole (b, d, and f). The single
cells are found in region S, whereas region M represents multicellular
clusters.
|
|
As could be expected from the MIC determinations according to NCCLS
guidelines, itraconazole was most active against the C43 isolate.
Maximal inhibition of up to 40% of control growth was obtained at 0.1 µM (0.07 µg · ml
1) itraconazole. No further
decrease in growth was observed at higher itraconazole concentrations,
a phenomenon known as residual or trailing growth (41). For
strains C48 and C56, 1 µM itraconazole reduced growth to 15 and 8%
of the control, respectively, indicating that strains C48 and C56
showed a more complete growth inhibition profile under these
experimental conditions. No enhanced clustering of cells was found in
the C48 and C56 isolates after exposure to 3 µM itraconazole compared
to C43 (Fig. 2). On the contrary, a higher proportion of single cells
was found in the two resistant isolates. The MICs according to the
NCCLS methodology, shown in Table 2, are far more discriminatory for
resistant strains C48 and C56 (16 and 32 times higher, respectively)
relative to the C43 value than the 50% inhibitory concentrations
(IC50s) for growth found under the ergosterol synthesis
experimental conditions. The very high level of residual growth
observed only for the C43 isolate could explain this difference.
Indeed, the NCCLS method was designed to minimize residual growth after
exposure to azoles in order to get as clear-cut MICs as possible. As
shown in Fig. 1b, ergosterol content in the C43 isolate was reduced at
lower itraconazole concentrations and the change from high to low
sterol content occurred over just 1 dilution step. By contrast,
reduction of ergosterol content from maximal to minimal levels in C48
and C56 occurred over 4 to 5 dilution steps. The IC50s
were, respectively, 0.02, 0.1, and 0.12 µM. The less steep slope of
the inhibition curve transitions in the two resistant isolates, C48 and
C56, resulted in even greater differences when inhibition of ergosterol content to 10% of control levels was taken as the endpoint. To reduce
ergosterol below 10% of control levels for C43, 0.025 µM itraconazole was sufficient, whereas in the case of C48 and C56, respectively, 0.6 and 0.7 µM, concentrations 24 and 28 times higher, were needed, respectively.
The products of ergosterol biosynthesis inhibition in the three
strains, measured by incorporation of radioactively labeled acetate,
showed considerable differences (Table
5). For isolate C43, 90% of the
radioactivity incorporated into sterols was found in the ergosterol
fraction; 50% inhibition of ergosterol synthesis was achieved at 0.002 µM itraconazole. Gas chromatography-mass spectrometry analysis
identified 3,6-diol as the major 14-methylated accumulation product in
cells exposed to 0.03 µM itraconazole, the lowest concentration
giving maximal inhibition. Other sterols found were
14
-methyl-ergosta-5,7,22,24(28)tetraene-3
ol, eburicol, lanosterol, obtusifoliol, and 14-methyl-fecosterol. In this strain, only minor quantities of obtusifolione, a 3-ketosteroid, were found.
With isolates C48 and C56, 50% inhibition of ergosterol synthesis was
reached at 0.05 and 0.04 µM itraconazole, respectively. In the
absence of azole antifungals, both isolates accumulated significant
amounts of 3,6-diol. The radioactivity incorporated into 3,6-diol
increased slightly when these isolates were incubated in the presence
of low itraconazole concentrations. After exposure to 0.3 µM
itraconazole, in addition to the accumulating sterols described above,
substantial quantities of obtusifolione were formed. This indicated
that, in these isolates, itraconazole interfered with the
4-demethylation process, as well as with cytochrome P-450-catalyzed 14
-demethylation. Accumulation of obtusifolione after exposure to
itraconazole was not observed in any of the 13 other strains studied
(data not shown).
ERG25 and ERG3 sequence analysis.
Obtusifolione is a substrate for the 3-ketoreductase stage in the
five-step 4-demethylation process, as shown in Fig.
3. So far, ERG25 is the only
gene identified in C. albicans in this process and its
product, the 4-methyloxidase, catalyzes at least three of the five
reactions required (1). Gachotte et al. identified the
ERG26 gene catalyzing the decarboxylase step in S. cerevisiae (10). Only the 3-ketoreductase reaction has
not yet been assigned to a gene. To investigate whether mutations in
the ERG25 gene, specific to both resistant isolates,
contributed to the inhibition of the 3-ketoreduction, we sequenced the
ERG25 alleles of the three isolates, as those of two
unrelated strains (C. albicans ATCC 44858 and B59630). All
isolates from patient V tested were heterozygotes in the
5'-untranslated region for the presence of four or five repeats of the
sequence ATTT starting at position 67 in the sequence with EMBL
accession no. AF051914. The sequences obtained from the reference
strains were identical; strain B59630 contained four ATTT repeats, as
found in the GenBank sequence obtained from C. albicans
CAI-8, whereas strain ATCC 44848 contained five ATTT repeats. The
ERG25 sequences of the two unrelated strains, B59630 and
ATCC 44848, were identical to the published sequence, whereas five
heterozygotic but silent mutations, A412A/C, A421A/G, A640A/T, A661A/G,
and G706G/T, were found to be identical in C43, C48, and C56. This
sequence analysis brings additional support for the relatedness of the
strains investigated here. The
5,6-desaturase is encoded
by ERG3. It is hypothesized that 3,6-diol is the presumed
product of attempted
5,6-desaturation of 14-methylated
precursors (14). Because accumulation of this sterol was
seen under control conditions, we sequenced the gene in all three
isolates. The 1,380-nucleotide amplification products were identical
for all three isolates. Compared to the sequence of C. albicans B311 deposited at GenBank, one silent heterozygotic
substitution (A1223A/G) and one T1438C mutation, leading to a conserved
change of valine into an alanine at position 352, were found. Because
this mutation was the same in all three isolates, it probably does not
contribute to the accumulation of 3,6-diol.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
The C4-demethylation process during
ergosterol biosynthesis. Reactions are shown to remove the first
C4-methyl group. To remove the second methyl group, the
entire process is repeated.
|
|
 |
DISCUSSION |
This study highlights the paradox that itraconazole reduces the
growth of resistant isolates C48 and C56 more profoundly, relative to
control growth, than that of parent susceptible isolate C43 under the
conditions of the present tests in vitro. However, the onset of growth
inhibition in the resistant isolates occurs at higher itraconazole
concentrations, presumably because intracellular azole content is
reduced as a result of enhanced expression of both CDR1 and
CDR2 in these strains. We hypothesize that the accumulation of obtusifolione as a result of itraconazole exposure, which is an
unusual phenomenon in C. albicans, contributes to the more complete inhibition of growth. Accumulation of obtusifolione induced by
itraconazole has been described in Histoplasma capsulatum
(35, 42) and Cryptococcus neoformans
(37). In both species, itraconazole inhibits growth
completely, to the baseline level. Obtusifolione is the substrate for
the 3-ketoreductase stage in the five-step 4-demethylation process, as
shown in Fig. 3. So far, ERG25 is the only gene identified
in C. albicans in this process and its product catalyzes at
least three of the five reactions required. In S. cerevisiae, the gene coding for the sterol decarboxylase was
recently identified as ERG26 (YGL001c) and found
to be essential in cells with no other deficiency in the sterol
biosynthetic pathway (10). The authors of this study
concluded that the accumulation of the toxic oxygenated sterol
intermediates prevented growth and that ERG26 was not
involved in the 3-ketoreductase reaction. Unfortunately, only limited
sequence information about a putative C. albicans ERG26
homolog is available. In addition, no accumulation of such carboxylic
acid sterols was observed in the C. albicans strains
studied. For these reasons, ERG26 was not further analyzed. Because in the 14
-demethylation process all three chemical steps necessary for the removal of the 14-methyl group are catalyzed by a
single cytochrome P-450 (ERG11 or CYP51), the
possibility exists that Erg25p is also involved in the 3-ketoreductase
reaction. No mutations in ERG25 were found in our isolates,
and thus, the ERG25 gene product is not likely to
participate in the obtusifolione accumulation. This sequence analysis,
however, does not conclusively eliminate the role of ERG25
in the 3-ketoreductase-catalyzed reaction. Indeed, because Erg25p is a
membrane-bound enzyme, the possibility exists that indirect effects
such as a different sterol composition, which influences membrane
fluidity, induce conformational changes in the enzyme in the resistant
strains, rendering it sensitive to itraconazole. The resistant isolates
differed from the sensitive strain in sterol composition in both the
quantity of ergosterol and in 3,6-diol content. It seems likely that
the whole ergosterol synthetic pathway is upregulated in the resistant
strains. The higher ergosterol content in the resistant isolates
correlates with the twofold higher transcription signal for
ERG11 described in these isolates by Sanglard et al.
(27). The unusual accumulation of 3,6-diol observed under
control conditions in the resistant isolates studied here was
previously described by Shimokawa et al. in a 14
-demethylase mutant
(32). We could not link the 3,6-diol accumulation to
mutations in the ERG3 sequence, whose product is
hypothesized to be involved in 3,6-diol formation. An alternative
explanation for the accumulation is that it arises as a result of
higher concentrations of 14-methylated substrates which could be
generated by an upregulation of early steps in the ergosterol pathway
followed by insufficient cytochrome P-450 activity to remove the
14
-methyl group from all of the substrate molecules available. The
less active 14
-demethylase enzyme could exist in the azole-resistant
strains investigated here. In fact, Sanglard et al. (30)
identified two point mutations, G129A and G464S, in C56
ERG11 that differed from the C43 sequence. They elegantly
showed that these point mutations specifically diminished the affinity
of the proteins for azole antifungals and demonstrated their
functionality by heterologous overexpression in an S. cerevisiae strain. However, these mutations might have affected
other features of these proteins, particularly their functional integrity.
From this study, it can be concluded that, as already shown by others
(8, 20), multiple changes are found in clonally related
clinical isolates. The observed azole resistance is probably due to the
combination of multiple factors that often evolve sequentially during
treatment. This complicates the interpretation of mechanistic resistance studies and highlights a need to obtain multiple clonal isolates from a patient at frequent intervals.
 |
ACKNOWLEDGMENTS |
We thank H. Schreuders, T. Verhulst, A. Schijfs, and L. Van
Nuffel for their excellent technical assistance and B. van den Hazel
for interesting discussions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Janssen Research
Foundation Infectious Diseases Research Departments, Turnhoutseweg 30, B2340 Beerse, Belgium. Phone: 32 14 60 31 97. Fax: 32 14 60 54 03. E-mail: pmaricha{at}janbe.jnj.com.
Present address: Department of Molecular Cell Biology, University
of Aberdeen Institute of Medical Sciences, Foresterhill, Aberdeen AB25
2ZD, Scotland.
 |
REFERENCES |
| 1.
|
Bard, M.,
D. A. Bruner,
C. A. Pierson,
N. D. Lees,
B. Biermann,
L. Frye,
C. Koegel, and R. Barbuch.
1996.
Cloning and characterization of ERG25, the Saccharomyces cerevisiae gene encoding C-4 sterol methyl oxidase.
Proc. Natl. Acad. Sci. USA
93:186-190[Abstract/Free Full Text].
|
| 2.
|
Bodey, G. P.
1997.
Resistance to antimicrobial agents revisited.
Curr. Opin. Infect. Dis.
10:419-421.
|
| 3.
|
De Muri, G. P., and M. K. Hostetter.
1995.
Resistance to antifungal agents.
Pediatr. Clin. N. Am.
42:665-685[Medline].
|
| 4.
|
Denning, D. W.,
G. G. Baily, and S. V. Hood.
1997.
Azole resistance in Candida.
Eur. J. Clin. Microbiol. Infect. Dis.
16:261-280[Medline].
|
| 5.
|
Doignon, F.,
M. Aigle, and P. Ribereau-Gayon.
1993.
Resistance to imidazoles and triazoles in Saccharomyces cerevisiae as a new dominant marker.
Plasmid
30:224-233[Medline].
|
| 6.
|
Dupont, B.
1995.
Azole antifungal agents: emerging and inherent resistance.
Curr. Opin. Infect. Dis.
8:424-427.
|
| 7.
|
Ebert, E.,
J. Gaudin,
W. Muecke,
K. Ramsteiner,
C. Vogel, and H. Fuhrer.
1983.
Inhibition of ergosterol biosynthesis by etaconazole in Ustilago maydis.
Z. Naturforsch.
38C:28-34.
|
| 8.
|
Franz, R.,
S. L. Kelly,
D. C. Lamb,
D. E. Kelly,
M. Ruhnke, and J. Morschhäuser.
1998.
Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.
Antimicrob. Agents Chemother.
42:3065-3072[Abstract/Free Full Text].
|
| 9.
|
Frosco, M., and J. F. Barrett.
1998.
Importance of antifungal drug-resistance: clinical significance and need for novel therapy.
Exp. Opin. Investig. Drugs
7:175-198.
|
| 10.
|
Gachotte, D.,
R. Barbuch,
J. Gaylor,
E. Nickel, and M. Bard.
1998.
Characterization of the Saccharomyces cerevisiae ERG26 gene encoding the C-3 sterol dehydrogenase (C-4 decarboxylase) involved in sterol biosynthesis.
Proc. Natl. Acad. Sci. USA
95:13794-13799[Abstract/Free Full Text].
|
| 11.
|
Hartman, P. G., and D. Sanglard.
1997.
Inhibitors of ergosterol as antifungal agents.
Curr. Pharm. Design
3:177-208.
|
| 12.
|
Hitchcock, C. A.,
K. J. Barrett-Bee, and N. J. Russell.
1986.
The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans.
J. Gen. Microbiol.
132:2421-2431[Medline].
|
| 13.
|
Johnson, E. M., and D. W. Warnock.
1995.
Azole drug resistance in yeast.
J. Antimicrob. Chemother.
36:751-755[Free Full Text].
|
| 14.
|
Joseph-Horn, T.,
D. W. Hollomon,
J. Loeffler, and S. Kelly.
1995.
Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.
Antimicrob. Agents Chemother.
39:1526-1529[Abstract].
|
| 15.
|
Joseph-Horn, T., and D. W. Hollomon.
1997.
Molecular mechanisms of azole resistance in fungi.
FEMS Microbiol. Lett.
149:141-149[Medline].
|
| 16.
|
Kelly, S. L.,
D. C. Lamb,
A. J. Corran,
B. C. Baldwin, and D. E. Kelly.
1995.
Mode of action and resistance to azole antifungals associated with the formation of 14 -methylergosta-8,24(28)-dien-3 ,6 -diol.
Biochem. Biophys. Res. Commun.
197:428-432.
|
| 17.
|
Kelly, S. L.,
D. C. Lamb,
D. E. Kelly,
N. J. Manning,
J. Loeffler,
H. Hebart,
U. Schumacher, and H. Einsele.
1997.
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol 5,6-desaturation.
FEBS Lett.
400:80-82[Medline].
|
| 18.
|
Kolaczkowski, M., and A. Goffeau.
1997.
Active efflux by multidrug transporters as one of the strategies to evade chemotherapy and novel practical implications of yeast pleiotropic drug resistance.
Pharmacol. Ther.
76:219-242[Medline].
|
| 19.
|
Lamb, D. C.,
D. E. Kelly,
W.-H. Schunck,
A. Z. Shyadehi,
M. Akhtar,
D. J. Lowe,
B. C. Baldwin, and S. L. Kelly.
1997.
The mutation T315A in Candida albicans sterol 14 -demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity.
J. Biol. Chem.
272:5682-5688[Abstract/Free Full Text].
|
| 20.
|
Lopez-Ribot, J.,
R. K. McAtee,
L. N. Lee,
W. R. Kirkpatrick,
T. C. White,
D. Sanglard, and T. F. Paterson.
1998.
Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Antimicrob. Agents Chemother.
42:2932-2937[Abstract/Free Full Text].
|
| 21.
|
Marichal, P., and H. Vanden Bossche.
1995.
Mechanisms of resistance to azole antifungals.
Acta Biochim. Pol.
42:509-516[Medline].
|
| 22.
|
Marichal, P.,
H. Vanden Bossche,
F. C. Odds,
G. Nobels,
D. W. Warnock,
Vincent Timmerman,
C. Van Broeckhoven,
S. Fay, and P. Mose-Larsen.
1997.
Molecular biological characterization of an azole-resistant Candida glabrata isolate.
Antimicrob. Agents Chemother.
41:2229-2237[Abstract].
|
| 23.
|
National Committee for Clinical Laboratory Standards.
1995.
Reference method for broth dilution susceptibility testing of yeasts. Tentative standard M27-A.
National Committee for Clinical Laboratory Standards, Villanova, Pa
|
| 24.
|
Odds, F. C.,
L. Vranckx, and F. Woestenborghs.
1995.
Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.
Antimicrob. Agents Chemother.
39:2051-2060[Abstract].
|
| 25.
|
Odds, F. C.
1998.
Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response?
Drug Resist. Updates
1:11-15.
[Medline] |
| 26.
|
Rex, J. H.,
M. G. Rinaldi, and M. A. Pfaller.
1995.
Resistance of Candida species to fluconazole.
Antimicrob. Agents Chemother.
39:1-8[Medline].
|
| 27.
|
Sanglard, D.,
K. Kuchler,
F. Ischer,
J. L. Pagani,
M. Monod, and J. Bille.
1995.
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.
Antimicrob. Agents Chemother.
39:2378-2386[Abstract].
|
| 28.
|
Sanglard, D.,
F. Ischer,
M. Monod, and J. Bille.
1996.
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.
Antimicrob. Agents Chemother.
40:2300-2305[Abstract].
|
| 29.
|
Sanglard, D.,
F. Ischer,
M. Monod, and J. Bille.
1997.
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.
Microbiology
143:405-416[Medline].
|
| 30.
|
Sanglard, D.,
F. Ischer,
L. Koymans, and J. Bille.
1998.
Amino acid substitutions in the cytochrome P450 lanosterol 14 -demethylase (CYP51) from azole-resistant Candida albicans clinical isolates contributing to the resistance to azole antifungal agents.
Antimicrob. Agents Chemother.
42:241-253[Abstract/Free Full Text].
|
| 31.
|
Sanglard, D.,
F. Ischer,
D. Calabrese,
M. de Micheli, and J. Bille.
1998.
Multiple resistance mechanisms to azole antifungals in yeast clinical isolates.
Drug Resist. Updates
1:255-265.
|
| 32.
|
Shimokawa, O.,
Y. Kato,
K. Kawano, and H. Nakayama.
1989.
Accumulation of 14 -methyl-ergosta-8,24(28)-diene-3 ,6 -diol in 14 -demethylation mutants of Candida albicans: genetic evidence for the involvement of 5-desaturase.
Biochim. Biophys. Acta
1003:15-19[Medline].
|
| 33.
|
Vanden Bossche, H.,
G. Willemsens,
W. Cools,
W. Lauwers, and L. Le Jeune.
1978.
Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans.
Chem. Biol. Interact.
21:59-78[Medline].
|
| 34.
|
Vanden Bossche, H.,
P. Marichal,
J. Gorrens,
D. Bellens,
H. Verhoeven,
M.-C. Coene,
W. Lauwers, and P. A. J. Janssen.
1987.
Interaction of azole derivatives with cytochrome P450 systems in yeast, fungi, plants and mammalian cells.
Pestic. Sci.
21:289-306.
|
| 35.
|
Vanden Bossche, H.,
P. Marichal,
J. Gorrens,
D. Bellens,
M.-C. Coene,
W. Lauwers,
L. Le Jeune,
H. Moereels, and P. A. J. Janssen.
1990.
Mode of action of antifungals of use in immunocompromised patients., p. 223-243.
In
H. Vanden Bossche, D. W. R. MacKenzie, G. Cauwenbergh, J. Van Cutsem, E. Drouhet, and B. Dupont (ed.), Mycoses in AIDS patients. Plenum Press, New York, N.Y
|
| 36.
|
Vanden Bossche, H.,
P. Marichal,
F. C. Odds,
L. Le Jeune, and M.-C. Coene.
1992.
Characterization of an azole-resistant Candida glabrata isolate.
Antimicrob. Agents Chemother.
36:2602-2610[Abstract/Free Full Text].
|
| 37.
|
Vanden Bossche, H.,
P. Marichal,
L. Le Jeune,
M.-C. Coene,
J. Gorrens, and W. Cools.
1993.
Effects of itraconazole on cytochrome P-450-dependent sterol 14 -demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans.
Antimicrob. Agents Chemother.
37:2101-2105[Abstract/Free Full Text].
|
| 38.
|
Vanden Bossche, H.,
P. Marichal, and F. C. Odds.
1994.
Molecular mechanisms of drug resistance in fungi.
Trends Microbiol.
2:393-400[Medline].
|
| 39.
|
Vanden Bossche, H.
1997.
Mechanisms of antifungal resistance.
Rev. Iberoam. Micol.
14:44-49.
|
| 40.
|
Vanden Bossche, H.,
F. Dromer,
L. Improvisi,
M. Lozano-Chiu,
J. H. Rex, and D. Sanglard.
1998.
Antifungal drug resistance in pathogenic fungi.
Med. Mycol.
36(Suppl. 1):119-128.
|
| 41.
|
Warnock, D. W., and E. M. Johnson.
1997.
Antifungal drug susceptibility testing.
Curr. Opin. Infect. Dis.
10:444-448.
|
| 42.
|
Wheat, J.,
P. Marichal,
H. Vanden Bossche,
A. Le Monte, and P. Connolly.
1997.
Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum.
Antimicrob. Agents Chemother.
41:410-414[Abstract].
|
| 43.
|
White, T. C.
1997.
The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 -demethylase in Candida albicans.
Antimicrob. Agents Chemother.
41:1488-1494[Abstract].
|
| 44.
|
White, T. C.,
R. A. Bowden, and K. A. Marr.
1998.
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
Clin. Microbiol. Rev.
11:382-402[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, November 1999, p. 2663-2670, Vol. 43, No. 11
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Parker, J. E., Merkamm, M., Manning, N. J., Pompon, D., Kelly, S. L., Kelly, D. E.
(2008). Differential Azole Antifungal Efficacies Contrasted Using a Saccharomyces cerevisiae Strain Humanized for Sterol 14{alpha}-Demethylase at the Homologous Locus. Antimicrob. Agents Chemother.
52: 3597-3603
[Abstract]
[Full Text]
-
Munayyer, H. K., Mann, P. A., Chau, A. S., Yarosh-Tomaine, T., Greene, J. R., Hare, R. S., Heimark, L., Palermo, R. E., Loebenberg, D., McNicholas, P. M.
(2004). Posaconazole Is a Potent Inhibitor of Sterol 14{alpha}-Demethylation in Yeasts and Molds. Antimicrob. Agents Chemother.
48: 3690-3696
[Abstract]
[Full Text]
-
Vanden Bossche, H., Ausma, J., Bohets, H., Vermuyten, K., Willemsens, G., Marichal, P., Meerpoel, L., Odds, F., Borgers, M.
(2004). The Novel Azole R126638 Is a Selective Inhibitor of Ergosterol Synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob. Agents Chemother.
48: 3272-3278
[Abstract]
[Full Text]
-
Barker, K. S., Pearson, M. M., Rogers, P. D.
(2003). Identification of genes differentially expressed in association with reduced azole susceptibility in Saccharomyces cerevisiae. J Antimicrob Chemother
51: 1131-1140
[Abstract]
[Full Text]
-
De Backer, M. D., Ilyina, T., Ma, X.-J., Vandoninck, S., Luyten, W. H. M. L., Vanden Bossche, H.
(2001). Genomic Profiling of the Response of Candida albicans to Itraconazole Treatment Using a DNA Microarray. Antimicrob. Agents Chemother.
45: 1660-1670
[Abstract]
[Full Text]